Navigation Links
Possible New Way to Detect, Monitor Liver Disease Without Painful Liver Biopsy

Hepatitis B Foundation says discovery suggests earlier treatment could

benefit patients

DOYLESTOWN, Pa., Dec. 19 /PRNewswire/ -- Scientists working at the Hepatitis B Foundation, in partnership with Drexel University College of Medicine, think they may have discovered a reliable alternative to liver biopsy for the early detection of liver fibrosis and cirrhosis, which afflict more than 5 million Americans. People with hepatitis B and C infections, as well as fatty liver diseases, are at greatest risk for progressing to cirrhosis that can lead to liver cancer.

Successful treatment depends on the early detection of fibrosis and cirrhosis. Currently, detection involves a surgical liver biopsy, which is an unpleasant, expensive procedure and carries some risk. Patients and doctors would prefer tests that are "not invasive" such as a blood test to detect and monitor liver disease.

Lead investigators Drs. Anand Mehta and Timothy Block report in the upcoming Journal of Virology, which appears online next week and in print February 2008, their discovery that the blood of most, if not all, people they tested with a diagnosis of liver cirrhosis, contains high levels of a special antibody that recognizes a carbohydrate sugar commonly found on bacteria. Detection of this antibody in the blood of an affected person correlates very well with a diagnosis of increasing fibrosis and cirrhosis in the new study.

"This is a fascinating discovery and is important because, if confirmed, the test could help us replace liver biopsy as a method for staging liver disease. In addition, it may be teaching us something about how liver disease occurs," said David Thomas, M.D., Chief, Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD.

Working with the National Cancer Institute (NCI) Early Detection Research Network, the researchers have been able to test this approach in 300 blood samples from people with liver disease, and can conduct the new test in thousands. Although the test is still experimental and more is needed before it can be used to monitor disease, the discovery is promising.

"If this work is validated, it may offer a new, non-invasive way to test for liver disease, allowing people to either avoid biopsy or to know when they really need one. It also implies that bacteria may have a much bigger role in initiating liver disease than realized, and even lead to new therapies," said Block.

Complications from bacteria in people with cirrhosis are well understood; however, bacteria are not usually seen early in the disease. The significance of this new discovery may suggest earlier treatments with antibiotics could benefit patients with chronic liver disease.

About the Hepatitis B Foundation

The Hepatitis B Foundation is the only national nonprofit organization solely dedicated to finding a cure and improving the quality of life for those affected with hepatitis B worldwide through research, education and patient advocacy. Visit or call (215) 489-4900 for more information.
Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Dr. Timothy Block Joan Block

SOURCE Hepatitis B Foundation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. The University of Nottingham in the British Midlands Announces Development of Possible Hepatitis C Vaccine
2. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
3. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
4. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
5. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
6. Boston Scientific Releases Remote Monitoring Data from its Wireless LATITUDE(R) Patient Management System
7. Cheetah Medicals NICOM Non-Invasive Cardiac Output Monitor Featured in a Presentation at the Heart Failure Society of America (HFSA) Annual Meeting
8. Adds Mobile Phone Capability Further Speeding Access to Experienced Monitors
9. Masimo Launches Patient SafetyNet and Showcases the Rainbow SET Upgradable Noninvasive Monitoring Platform at 2007 ASA Annual Meeting
10. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
11. Oridion Launches its Fully Integrated Remote Monitoring System and SARA Software for Improved Patient Safety
Post Your Comments:
(Date:11/25/2015)... DIEGO , Nov. 25, 2015  Neurocrine Biosciences, ... Kevin Gorman , President and CEO of Neurocrine Biosciences, ... Healthcare Conference in New York . ... to visit the website approximately 5 minutes prior to ... A replay of the presentation will be available on ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... company uBiome, were featured on AngelList early in their initial angel funding process. ... AngelList syndicate for individuals looking to make early stage investments in the microbiome ...
(Date:11/24/2015)... Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" or ... financial results for the quarter ended September 30, ... Canadian dollars and presented under International Financial Reporting ... ," said Andrew Rae , President ... iCo-008 are not only value enriching for this ...
(Date:11/24/2015)... , November 24, 2015 ... market research report "Oligonucleotide Synthesis Market by Product & ... Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & ... by MarketsandMarkets, the market is expected to reach USD ... 2015, at a CAGR of 10.1% during the forecast ...
Breaking Biology Technology:
(Date:11/17/2015)... Paris from 17 th ... Paris from 17 th until 19 th ... leader, has invented the first combined scanner in the world ... scanning surface. Until now two different scanners were required: one ... both on the same surface. This innovation is an ...
(Date:11/16/2015)... JOSE, Calif. , Nov 16, 2015 /PRNewswire/ ... developer of human interface solutions, today announced expansion ... Synaptics TouchView ™ touch controller and display ... architectural revolution of smartphones. These new TDDI products ... include TD4100 (HD resolution), TD4302 (WQHD resolution), and ...
(Date:11/11/2015)... MINNETONKA, Minn. , Nov. 11, 2015   MedNet ... the entire spectrum of clinical research, is pleased to announce ... Partnerships in Clinical Trials (PCT) event, to be held ... will be able to view live demonstrations of ... platform, and learn how iMedNet has been able ...
Breaking Biology News(10 mins):